US FDA Generic Drug Approvals, Other Actions Declined As Approval Times Climbed In FY 2024

An increase in complex product submissions may explain median and mean approval time increases for ANDAs, but fewer actions across many categories could be a concern.

Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medication.
The FY 2024 generic drugs activity data likely will inform user fee reauthorization negotiations, which will begin in 2025. • Source: Alamy

More from Regulation

Regulatory Recap: AAM Looks To Confirmed HHS Secretary RFK Jr. To Fix ‘Broken System’

 

Generics Bulletin reviews the latest regulatory developments across the world.

Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm

 
• By 

Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.

AAM Stares Into The Biosimilar Void

 
• By 

Discussing a new report highlighting the lack of US biosimilar competition on the cards for the majority of biologics losing exclusivity in the next ten years, the AAM’s Access! 2025 conference heard that the “sobering” findings should act as a “wake-up call for stakeholders.”

User Fees: Industry Should Push For Extension Of Current Agreement In Reconciliation Bill, Gottlieb Says

 
• By 

Trump’s former FDA commissioner sees ‘nothing good’ coming from negotiating a new user fee agreement in the ‘current political environment.’

More from Generics Bulletin

NHS And Sandoz Look Into Natalizumab Switching Reports

 
• By 

The UK’s NHS and Sandoz have both told Generics Bulletin that they are looking into reports from a single UK hospital of adverse reactions linked to patients that have switched from Tysabri to Sandoz’s Tyruko biosimilar.

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence

 
• By 

With sales remaining sluggish, on the back of fewer launches, Glenmark’s management nevertheless struck an upbeat tone when discussing the firm’s prospects in the US moving into the company’s 2026 financial year.

More Stelara Rivals Hit US, With Discounts Already Reaching 90%

 
• By 

As more Stelara biosimilars pile into the US market – including launches from Alvotech/Teva, Samsung Bioepis/Sandoz and Biocon Biologics – the latest data suggests that price competition for ustekinumab rivals could be fierce, with all three companies confirming to Generics Bulletin details of significant discounts to the brand.